Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo

Christina A. Pacak, Cathryn S. Mah, Bijoy D. Thattaliyath, Thomas J. Conlon, Melissa A. Lewis, Denise E. Cloutier, Irene Zolotukhin, Alice F Tarantal, Barry J. Byrne

Research output: Contribution to journalArticle

275 Citations (Scopus)

Abstract

Heart disease is often the end result of inherited genetic defects, which may potentially be treatable using a gene-transfer approach. Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a realistic method for the treatment of such disorders. Here, we demonstrate and compare the natural affinity of specific AAV serotype capsids for transduction of cardiac tissue. We compared the previously accepted optimal rAAV serotype for transduction of skeletal muscle, rAAV2/1, with rAAV2/8 and the newer rAAV2/9 vectors carrying the CMV-lacZ construct in their respective abilities to transcend vasculature and transduce myocardium following intravenous delivery of 1×10 vector genomes in neonatal mice. We found that both rAAV2/8 and rAAV2/9 are able to transduce myocardium at ≈20- and 200-fold (respectively) higher levels than rAAV2/1. Biodistribution analysis revealed that rAAV2/9 and rAAV2/8 demonstrate similar behavior in extracardiac tissue. Vector genome quantification showed an increase in genome copy numbers in cardiac tissue for several weeks following administration, which corresponds to expression data. In addition, we intravenously administered 1×10 vector genomes of rAAV2/9-CMV-lacZ into adult mice and achieved an expression biodistribution profile similar to that found following delivery to newborns. Although higher doses of virus will be necessary to approach those levels observed following neonatal injections, adult myocardium is also readily transduced by rAAV2/9. Finally, we have demonstrated physiological disease correction by AAV9 gene transfer in a mouse model of Pompe disease via ECG tracings and that intravenous delivery of the same vector preferentially transduces cardiac tissue in nonhuman primates.

Original languageEnglish (US)
JournalCirculation Research
Volume99
Issue number4
DOIs
StatePublished - Aug 2006

Fingerprint

Dependovirus
Genome
Myocardium
Glycogen Storage Disease Type II
Genes
Aptitude
Capsid
Primates
Heart Diseases
Electrocardiography
Skeletal Muscle
Viruses
Injections
Serogroup
Therapeutics

Keywords

  • AAV9
  • Adeno-associated virus
  • Cardiomyopathy
  • Gene therapy
  • Gene transfer

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., ... Byrne, B. J. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circulation Research, 99(4). https://doi.org/10.1161/01.RES.0000237661.18885.f6

Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. / Pacak, Christina A.; Mah, Cathryn S.; Thattaliyath, Bijoy D.; Conlon, Thomas J.; Lewis, Melissa A.; Cloutier, Denise E.; Zolotukhin, Irene; Tarantal, Alice F; Byrne, Barry J.

In: Circulation Research, Vol. 99, No. 4, 08.2006.

Research output: Contribution to journalArticle

Pacak, CA, Mah, CS, Thattaliyath, BD, Conlon, TJ, Lewis, MA, Cloutier, DE, Zolotukhin, I, Tarantal, AF & Byrne, BJ 2006, 'Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo', Circulation Research, vol. 99, no. 4. https://doi.org/10.1161/01.RES.0000237661.18885.f6
Pacak, Christina A. ; Mah, Cathryn S. ; Thattaliyath, Bijoy D. ; Conlon, Thomas J. ; Lewis, Melissa A. ; Cloutier, Denise E. ; Zolotukhin, Irene ; Tarantal, Alice F ; Byrne, Barry J. / Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. In: Circulation Research. 2006 ; Vol. 99, No. 4.
@article{2c38bce5a0ed49d3a91dad1b2463bc03,
title = "Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo",
abstract = "Heart disease is often the end result of inherited genetic defects, which may potentially be treatable using a gene-transfer approach. Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a realistic method for the treatment of such disorders. Here, we demonstrate and compare the natural affinity of specific AAV serotype capsids for transduction of cardiac tissue. We compared the previously accepted optimal rAAV serotype for transduction of skeletal muscle, rAAV2/1, with rAAV2/8 and the newer rAAV2/9 vectors carrying the CMV-lacZ construct in their respective abilities to transcend vasculature and transduce myocardium following intravenous delivery of 1×10 vector genomes in neonatal mice. We found that both rAAV2/8 and rAAV2/9 are able to transduce myocardium at ≈20- and 200-fold (respectively) higher levels than rAAV2/1. Biodistribution analysis revealed that rAAV2/9 and rAAV2/8 demonstrate similar behavior in extracardiac tissue. Vector genome quantification showed an increase in genome copy numbers in cardiac tissue for several weeks following administration, which corresponds to expression data. In addition, we intravenously administered 1×10 vector genomes of rAAV2/9-CMV-lacZ into adult mice and achieved an expression biodistribution profile similar to that found following delivery to newborns. Although higher doses of virus will be necessary to approach those levels observed following neonatal injections, adult myocardium is also readily transduced by rAAV2/9. Finally, we have demonstrated physiological disease correction by AAV9 gene transfer in a mouse model of Pompe disease via ECG tracings and that intravenous delivery of the same vector preferentially transduces cardiac tissue in nonhuman primates.",
keywords = "AAV9, Adeno-associated virus, Cardiomyopathy, Gene therapy, Gene transfer",
author = "Pacak, {Christina A.} and Mah, {Cathryn S.} and Thattaliyath, {Bijoy D.} and Conlon, {Thomas J.} and Lewis, {Melissa A.} and Cloutier, {Denise E.} and Irene Zolotukhin and Tarantal, {Alice F} and Byrne, {Barry J.}",
year = "2006",
month = "8",
doi = "10.1161/01.RES.0000237661.18885.f6",
language = "English (US)",
volume = "99",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo

AU - Pacak, Christina A.

AU - Mah, Cathryn S.

AU - Thattaliyath, Bijoy D.

AU - Conlon, Thomas J.

AU - Lewis, Melissa A.

AU - Cloutier, Denise E.

AU - Zolotukhin, Irene

AU - Tarantal, Alice F

AU - Byrne, Barry J.

PY - 2006/8

Y1 - 2006/8

N2 - Heart disease is often the end result of inherited genetic defects, which may potentially be treatable using a gene-transfer approach. Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a realistic method for the treatment of such disorders. Here, we demonstrate and compare the natural affinity of specific AAV serotype capsids for transduction of cardiac tissue. We compared the previously accepted optimal rAAV serotype for transduction of skeletal muscle, rAAV2/1, with rAAV2/8 and the newer rAAV2/9 vectors carrying the CMV-lacZ construct in their respective abilities to transcend vasculature and transduce myocardium following intravenous delivery of 1×10 vector genomes in neonatal mice. We found that both rAAV2/8 and rAAV2/9 are able to transduce myocardium at ≈20- and 200-fold (respectively) higher levels than rAAV2/1. Biodistribution analysis revealed that rAAV2/9 and rAAV2/8 demonstrate similar behavior in extracardiac tissue. Vector genome quantification showed an increase in genome copy numbers in cardiac tissue for several weeks following administration, which corresponds to expression data. In addition, we intravenously administered 1×10 vector genomes of rAAV2/9-CMV-lacZ into adult mice and achieved an expression biodistribution profile similar to that found following delivery to newborns. Although higher doses of virus will be necessary to approach those levels observed following neonatal injections, adult myocardium is also readily transduced by rAAV2/9. Finally, we have demonstrated physiological disease correction by AAV9 gene transfer in a mouse model of Pompe disease via ECG tracings and that intravenous delivery of the same vector preferentially transduces cardiac tissue in nonhuman primates.

AB - Heart disease is often the end result of inherited genetic defects, which may potentially be treatable using a gene-transfer approach. Recombinant adeno-associated virus (rAAV)-mediated gene delivery has emerged as a realistic method for the treatment of such disorders. Here, we demonstrate and compare the natural affinity of specific AAV serotype capsids for transduction of cardiac tissue. We compared the previously accepted optimal rAAV serotype for transduction of skeletal muscle, rAAV2/1, with rAAV2/8 and the newer rAAV2/9 vectors carrying the CMV-lacZ construct in their respective abilities to transcend vasculature and transduce myocardium following intravenous delivery of 1×10 vector genomes in neonatal mice. We found that both rAAV2/8 and rAAV2/9 are able to transduce myocardium at ≈20- and 200-fold (respectively) higher levels than rAAV2/1. Biodistribution analysis revealed that rAAV2/9 and rAAV2/8 demonstrate similar behavior in extracardiac tissue. Vector genome quantification showed an increase in genome copy numbers in cardiac tissue for several weeks following administration, which corresponds to expression data. In addition, we intravenously administered 1×10 vector genomes of rAAV2/9-CMV-lacZ into adult mice and achieved an expression biodistribution profile similar to that found following delivery to newborns. Although higher doses of virus will be necessary to approach those levels observed following neonatal injections, adult myocardium is also readily transduced by rAAV2/9. Finally, we have demonstrated physiological disease correction by AAV9 gene transfer in a mouse model of Pompe disease via ECG tracings and that intravenous delivery of the same vector preferentially transduces cardiac tissue in nonhuman primates.

KW - AAV9

KW - Adeno-associated virus

KW - Cardiomyopathy

KW - Gene therapy

KW - Gene transfer

UR - http://www.scopus.com/inward/record.url?scp=33747518710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747518710&partnerID=8YFLogxK

U2 - 10.1161/01.RES.0000237661.18885.f6

DO - 10.1161/01.RES.0000237661.18885.f6

M3 - Article

C2 - 16873720

AN - SCOPUS:33747518710

VL - 99

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 4

ER -